Abivax (ABVX) Common Equity (2023 - 2026)
Abivax (ABVX) posted quarterly Common Equity of $502.9 million for Q1 2026, up 7353.3% year-over-year from $6.7 million in Q1 2025, and down 5.08% quarter-over-quarter from $529.9 million in Q4 2025.
Abivax (ABVX) Common Equity (2023 - 2026) Analysis & Trends
Abivax's Common Equity history runs 4 years deep, the most recent figure standing at $502.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 7353.3% year-over-year to $502.9 million; the TTM figure through Mar 2026 stood at $502.9 million (up 7353.3% YoY), while the FY2025 annual figure was $529.9 million, up 1121.34% from the prior year.
- Common Equity for Q1 2026 stood at $502.9 million, down from $529.9 million in the prior quarter.
- The five-year high for Common Equity was $597.7 million in Q3 2025, with the low at -$54.7 million in Q2 2025.
- The 4-year median for Common Equity is $173.5 million (2023), against an average of $244.9 million.
- The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 140.13% in 2025, then jumped 7353.3% in 2026.
- Abivax's Common Equity stood at $210.9 million in 2023, then plunged by 79.43% to $43.4 million in 2024, then soared by 1121.34% to $529.9 million in 2025, then decreased by 5.08% to $502.9 million in 2026.
- Business Quant data shows ABVX's Common Equity at $502.9 million in Q1 2026, $529.9 million in Q4 2025, and $597.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 502.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 502.95 Mn |
| Dec 31, 2025 | 529.88 Mn |
| Sep 30, 2025 | 597.67 Mn |
| Jun 30, 2025 | -54.65 Mn |
| Mar 31, 2025 | -6.93 Mn |
| Dec 31, 2024 | 43.38 Mn |
| Jun 30, 2024 | 136.19 Mn |
| Dec 31, 2023 | 210.89 Mn |